New York, January 31, 2026, 16:40 (ET) — Market closed.
Abbott Laboratories (ABT) shares closed Friday roughly 3% higher, settling at $109.30. During the session, the stock fluctuated between $105.72 and $109.47.
The market turned uneasy as stocks dipped following Donald Trump’s nomination of Kevin Warsh to head the Federal Reserve, coupled with producer prices rising more than anticipated, according to a Reuters report. Michael Hans from Citizens Wealth described the moves as the market “calibrating” to the new Fed leadership and its policy direction. Reuters
Abbott’s latest move follows persistent jitters after its quarterly results. On January 22, the company reported $11.46 billion in revenue, falling short of estimates. It also projected first-quarter adjusted earnings between $1.12 and $1.18 per share, below analyst expectations. Nutrition sales dropped 8.9% to $1.94 billion, while diagnostics revenue declined 2.5% to $2.46 billion. CEO Robert B. Ford warned that nutrition growth would remain “challenged” for a few quarters. Meanwhile, Bernstein’s Christian Moore highlighted a potential “negative aura” around infant formula, as competitors like Nestlé, Danone, and Lactalis recalled products amid contamination concerns. Reuters
Abbott’s earnings release outlined a forecast for full-year 2026 organic sales growth between 6.5% and 7.5% — excluding currency fluctuations and other non-core factors. Adjusted diluted earnings per share are expected to hit $5.55 to $5.80, factoring out certain items. The company reaffirmed its plan to complete the Exact Sciences acquisition in Q2 and highlighted recent FDA and European approvals for its heart-rhythm devices.
A recent filing with the U.S. Securities and Exchange Commission revealed that Ford purchased 18,800 shares of Abbott on January 23. The shares were acquired at a weighted average price near $107.13 each, totaling around $2.0 million. The transaction was made through the Ford Family Trust.
Medical-device stocks are bouncing from one headline to the next, with tariffs shaking things up again. Stryker boosted its full-year profit outlook this week. CEO Kevin A. Lobo noted the company heads into 2026 with “significant momentum,” despite warning of a heavier tariff impact in the first half. Reuters
Abbott traders will be eyeing Monday’s open to see if Friday’s move holds up as volume picks back up and the tape finds a direction. Right now, risk appetite is driving more than just the latest company news.
Abbott’s immediate outlook hinges on two clear factors: if nutrition demand holds steady following recent price hikes, and whether the diagnostics segment can shake off its current slump amid challenging comparisons. Devices still act as the wildcard, but investors seem to be sizing up the entire picture as a single package.
Nutrition could remain sluggish longer than investors anticipate, or tougher pricing pressure may weigh on growth unevenly. If policy news keeps rates and stocks jittery, demand for defensive plays can evaporate fast.
February 6 brings the next major macro event: the U.S. jobs report. Between now and then, a packed earnings calendar will likely shape market mood, according to a Reuters analysis. For Abbott, this broader context could carry as much weight as any new company-specific news.
